Background: Histopathologic grading and clinical staging cannot provide a precise prognosis of oral cavity cancer patients.

Conclusions: The prognosis of oral cavity cancer has improved significantly from the early 1970s to recent years.

However, guidelines for the treatment of most forms of HNSCC do not exist in German-speaking countries with the exception of oral cavity cancer.

The objective of this study was to determine the efficacy of paclitaxel and PKI166, a novel inhibitor of EGFR, against oral cavity cancer.

We aimed to evaluate temporal trends in demographics, treatment, and prognosis of oral cavity cancer diagnosed between 1973 and 2014 inclusive.

There are limited data suggesting a change in prognosis of oral cavity cancers.

The incidence rates of potentially HPV-associated oropharyngeal and oral cavity cancers by various characteristics were estimated.

In particular, HPV is strongly associated with the development of oropharyngeal cancer and a small minority of oral cavity cancers.

Conclusions: NLR was first shown to be significantly elevated in oral cavity cancers and in oral cavity SCC in this study.

The current methodology described in this article should therefore afford pathologists original and quantitative (and thus objective) prognostic markers for oral cavity cancers.

Methods: This is a retrospective analysis of prospectively collected data of patients undergoing induction chemotherapy (IC) in oral cavity cancers from 2010 to 2012.